CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
tanespimycin +1 moredrug
Likely dose
Not stated in record
Key inclusion· 8
  • ✓Histologically confirmed adenocarcinoma of the prostate with metastatic disease
  • ✓Measurable or evaluable disease with PSA ≥5 ng/mL OR new bony metastases on bone scan
  • ✓Objective disease progression or rising PSA despite androgen deprivation therapy (with 2 successive PSA elevations ≥1 week apart)
  • ✓Castrate testosterone level (<50 ng/mL) with continued LHRH agonist therapy during study
Key exclusion· 10
  • ✕Brain metastases requiring active therapy (though previously treated asymptomatic metastases allowed)
  • ✕Serious allergy to eggs (hypotension, dyspnea, anaphylaxis, or edema)
  • ✕Myocardial infarction within past year
  • ✕Cerebrovascular accident or transient ischemic attack within past 6 months

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00118092
NCT00118092Phase 2Completed
CompareCT.gov

A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Hormone-Refractory Metastatic Prostate Cancer

National Cancer Institute (NCI)·interventional·Posted Jul 11, 2005·Updated Apr 18, 2017

In Brief

A Phase 2 clinical trial evaluating tanespimycin and laboratory biomarker analysis for Adenocarcinoma of the Prostate and 2 related conditions. Completed, enrolled 17 participants across 1 site.

Detailed Summary

This phase II trial is studying how well 17-AAG works in treating patients with metastatic prostate cancer that did not respond to previous hormone therapy. Drugs used in chemotherapy, such as 17-AAG, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 11, 2005
Enrollment StartJan 1, 2005
Primary CompletionMay 1, 2006
Study CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 21.0 years ago

Interventions

tanespimycindrug

Given IV

laboratory biomarker analysisother

Correlative studies